RESEARCH AND DEVELOPMENT COLLABORATIVE AGREEMENTS (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Research and development collaborative agreements
Total recognized revenue	$ 1,845,021	$ 1,060,057	$ 4,396,132	$ 4,743,170
Collaborative agreements | Pfizer Inc.
Research and development collaborative agreements
Cost reimbursements				1,916,250
Amortization of license and development fees	1,845,021	1,060,057	4,336,036	2,826,920
Total recognized revenue	1,845,021	1,060,057	4,336,036	4,743,170
Collaborative agreements | Pfizer Inc. | Maximum
Research and development collaborative agreements
Eligible milestone payment to be received, on exercise of option for worldwide rights to iSONEP by counterparty	$ 497,500,000		$ 497,500,000